Reverse phase protein microarrays advance to use in clinical trials
about
Reverse phase protein arrays in signaling pathways: a data integration perspectiveLevels of soluble E-cadherin in breast, gastric, and colorectal cancersQuantitative phenotypic and pathway profiling guides rational drug combination strategiesFunctional protein microarray as molecular decathlete: a versatile player in clinical proteomicsOne-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimensReverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical UseCapillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnosticsSemi-quantitative measurement of specific proteins in human cumulus cells using reverse phase protein arrayElevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors.Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples.MALDI imaging mass spectrometry--painting molecular picturesSystems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells.Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead."The quest for biomarkers": are we on the right technical track?Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinomaLaser capture microdissection for protein and NanoString RNA analysisAnalytical challenges translating mass spectrometry-based phosphoproteomics from discovery to clinical applications.A multi-parametric microarray for protein profiling: simultaneous analysis of 8 different cytochromes via differentially element tagged antibodies and laser ablation ICP-MS.Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers.Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways.Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases.Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancerCancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodelingPrecision oncology based on omics data: The NCT Heidelberg experience.Immunocapture strategies in translational proteomics.Reverse phase protein arrays: mapping the path towards personalized medicine.Is phosphoproteomics ready for clinical research?Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress.The current state of the art of quantitative phosphoproteomics and its applications to diabetes researchThe RasGAP gene, RASAL2, is a tumor and metastasis suppressorTissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.Integration of proteomics into systems biology of cancer.Recent advances in protein-protein interaction prediction: experimental and computational methods.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.Application of molecular technologies for phosphoproteomic analysis of clinical samples.Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.An overview of innovations and industrial solutions in Protein Microarray Technology.
P2860
Q26799716-68A64291-10BB-4B7C-AAFA-64119758989FQ27012638-B8A755D9-8092-4E23-9071-E63F9E67284DQ27021150-5B68B19B-E925-46E4-A164-C480CAB55612Q27025953-6BE83DEF-B4E3-462C-AB01-017497F52459Q27323289-9D09F132-323D-47A1-89E3-E7AFD05A615DQ28083256-34F8001F-3C74-4429-AEA0-BC3962A7597AQ28396457-5A2777B7-50E4-472C-8935-68F777C5A916Q28657731-5426FEAC-1AB8-4F26-A37C-B607906504E7Q30439048-B64F5F25-5666-4A3E-A8D6-656678327BE0Q30449408-5BE9D2E6-BDFD-4E4D-BE33-63DCEF2CFA3BQ30472639-EF04BD4B-76C2-4C5F-AAFC-FE1ED3C2ED23Q30549646-F5C94B4B-C2E6-4602-9F88-E02BE766AEC9Q33603472-1394F440-0AE0-4FEF-B378-E60255BC6F6EQ33850616-637E9204-944F-4E02-BF4B-65AFA2819F68Q33891197-1EB1357C-34B2-4385-AB5A-9135DF6D00FEQ34116103-ED742472-45D9-48EA-9D62-1FD006982D9CQ34420593-0B37627B-D59F-4680-BD3B-088B5A035681Q34425869-50349213-E569-4A2A-BB65-71358A5906B6Q34604043-3751FD9D-BD56-4E20-B17F-154236FDC3DEQ34748239-EAADAFC9-87E1-4CF0-A67B-BD262AACDAF4Q34777067-159BBE20-EA6F-49EA-A4A0-F2964EAE068BQ35082315-5B20BA8F-9108-4C48-A3BC-D1FF42ED6231Q35128103-6B2894BE-777A-40A9-8C4E-B31F3EBC907FQ35219054-C131F28A-71B5-4031-AC07-9818800DE756Q36097185-09DC3D5F-BB9E-41C9-96AB-87354FD582CCQ36228895-6B8D80BE-A7D6-48BF-B5C2-DD9D5F15CBD7Q36396606-098528BE-E09D-4B7A-8189-5A1EE0572C9CQ36519000-902A787F-7470-4524-9505-AFEBCC186455Q36519831-A8E2D2AA-A978-4B79-BB8A-8B5483E1CDACQ36799469-B7A16DE9-E2D3-49D0-8A95-93A68A5B8259Q37055774-0CAEDAE1-4D87-40C2-89FC-D15FFDDE8013Q37080936-4B78AB56-B9A2-4900-BDC8-62F0596854CDQ37293348-4BE63604-2EC5-4C94-9122-892DF7D86D2AQ37805245-1D11DD92-25C9-4ECB-99F8-3CEB5B624412Q37992554-9A8E6376-55AC-48A7-BF1C-5E9E314EFE25Q38014488-F97F99BE-9F60-49FB-8918-C395FB4CAA4EQ38148583-5901EC9C-8724-4C1D-995F-703301625822Q38194417-26DA1CEC-AB5F-4088-A927-94B6C7B9F3C9Q38238613-E0B5A604-EECA-440B-A61E-DA76C93DDA5BQ38560159-6F90FAB1-19E9-4247-A740-79AE33BBDF85
P2860
Reverse phase protein microarrays advance to use in clinical trials
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Reverse phase protein microarrays advance to use in clinical trials
@ast
Reverse phase protein microarrays advance to use in clinical trials
@en
Reverse phase protein microarrays advance to use in clinical trials
@nl
type
label
Reverse phase protein microarrays advance to use in clinical trials
@ast
Reverse phase protein microarrays advance to use in clinical trials
@en
Reverse phase protein microarrays advance to use in clinical trials
@nl
prefLabel
Reverse phase protein microarrays advance to use in clinical trials
@ast
Reverse phase protein microarrays advance to use in clinical trials
@en
Reverse phase protein microarrays advance to use in clinical trials
@nl
P2860
P1433
P1476
Reverse phase protein microarrays advance to use in clinical trials
@en
P2093
Claudius Mueller
Lance A Liotta
P2860
P304
P356
10.1016/J.MOLONC.2010.09.003
P407
P577
2010-12-01T00:00:00Z